Skip to main content
. 2022 Apr 3;14(4):783. doi: 10.3390/pharmaceutics14040783

Table 2.

Composition of AGN-PLHNPs obtained from the 33-BBD, with actual and predicted experimental values of their respective responses.

Independent Variables Dependent Variables Zeta Potential
(mV)
PDI
Runs F1
(PLGA;
mg/mL)
F2
(PL-90G;
(mg/mL)
F3
(P-188;
% w/v)
R1
(PS; nm)
R2
(EE; %)
R3
(CDR; %)
F1 7 9 1 136.03 72.04 85.29 −20.3 0.21
F2 11 5 1 140.56 69.89 79.96 −22.9 0.19
F3 11 9 1 175.26 81.14 71.21 −23.5 0.18
F4 7 7 1.25 106.24 66.24 93.31 −20.3 0.17
F5 11 7 0.75 169.85 75.78 71.33 −16.2 0.19
F6 9 5 1.25 108.74 62.45 90.14 −19.6 0.22
F7 7 5 1 101.93 58.35 90.8 −22.6 0.19
F8 7 7 0.75 131.39 59.37 83.88 −17.4 0.23
F9 9 9 1.25 143.76 77.72 82.03 −15.8 0.19
F10 11 7 1.25 149.84 75.27 79.62 −16.9 0.23
F11 9 7 1 126.34 76.87 81.78 −25.3 0.17
F12 9 7 1 125.62 78.45 82.76 −24.8 0.19
F13 9 5 0.75 133.39 62.39 80.21 −20.1 0.22
F14 9 9 0.75 167.71 70.68 73.05 −18.5 0.18
F15 9 7 1 126.07 77.11 82.23 −24.5 0.19
HHS Vulnerability Disclosure